A Vancouver biotechnology company that has found a way to halt abnormal blood-cell growth to combat a range of disorders from leukemia to allergic reactions has scooped up $14.5 million US in venture capital funding from local and U.S. investors. In one of the largest early-stage financings in B.C.'s recent biotech history, Aquinox Pharmaceuticals, a spin-off from the University of B.C. and the B.C. Cancer Agency, has made a deal that will see it through to the first clinical trials of its lead drug AQX-MN100, a treatment for cancer and inflammatory disease. Source.